Pomalidomide | CC-4047 | CAS#19171-19-8 | TGFbeta inhibitor

MedKoo Cat#: 202310 | Name: Pomalidomide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.

Chemical Structure

Pomalidomide

CAS#19171-19-8

Theoretical Analysis

MedKoo Cat#: 202310

Name: Pomalidomide

CAS#: 19171-19-8

Chemical Formula: C13H11N3O4

Exact Mass: 273.0750

Molecular Weight: 273.24

Elemental Analysis: C, 57.14; H, 4.06; N, 15.38; O, 23.42

Price and Availability

Size	Price	Availability
500mg	USD 90.00	Ready to ship
1g	USD 150.00	Ready to ship
2g	USD 225.00	Ready to ship
5g	USD 450.00	Ready to ship
10g	USD 800.00	Ready to ship
20g	USD 1,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CC4047; CC 4047; CC-4047; Pomalidomide. Brand name: Pomalyst.

IUPAC/Chemical Name

4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

InChi Key

UVSMNLNDYGZFPF-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

SMILES Code

O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3N)=O

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# A8T06K23

QC Data

View QC data: current batch, Lot#A8T06K23

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Pomalidomide is the third-generation immunomodulatory agent, functions through interacting with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.

In vitro activity:

Here, treatment of PEL cells with Pom (Pomalidomide) restores NK cell lysis and T-cell activation, and this is directly due to the upregulation of the co-stimulatory molecules ICAM-1 and B7-2, as specific blocking antibodies to these proteins prevent the responses. To this study’s knowledge, this is the first report of otherwise “immunologically silent” PELs being specifically sensitized for recognition and lysis by T-cells and NK-cells, both of which are important components of anti-tumor immunity. The mechanistic studies further provide evidence that these effects occur through Pom’s effects on the E3 ubiquitin ligase cereblon and, at least in part, involve the PI3K pathway. Reference: PLoS Pathog. 2021 Jan; 17(1): e1009091. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817053/

In vivo activity:

POM (Pomalidomide) showed a negative impact on proliferation of Raji and OCI-LY10 cells (Figure 2) and significant preclinical therapeutic activity against CNS lymphoma in both Raji and OCI-LY10 murine orthotopic models. The in vivo findings showed a dose-dependent therapeutic activity against CNS lymphoma with statistically significant therapeutic activity at 3 mg, 10 mg, and 30 mg/kg dose levels of POM in terms of reduction of tumor growth and prolongation of survival (Figure 3). Reference: PLoS One. 2013; 8(8): e71754. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734315/

	Solvent	mg/mL	mM
Solubility
	DMSO	15.0	54.90

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 273.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Shrestha P, Davis DA, Jaeger HK, Stream A, Aisabor AI, Yarchoan R. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2. PLoS Pathog. 2021 Jan 7;17(1):e1009091. doi: 10.1371/journal.ppat.1009091. PMID: 33411730; PMCID: PMC7817053. 2. Davis DA, Shrestha P, Aisabor AI, Stream A, Galli V, Pise-Masison CA, Tagawa T, Ziegelbauer JM, Franchini G, Yarchoan R. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. Oncoimmunology. 2018 Dec 5;8(2):e1546544. doi: 10.1080/2162402X.2018.1546544. PMID: 30713808; PMCID: PMC6343774. 3. Casu MA, Mocci I, Isola R, Pisanu A, Boi L, Mulas G, Greig NH, Setzu MD, Carta AR. Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson's Disease. Front Aging Neurosci. 2020 Feb 13;12:31. doi: 10.3389/fnagi.2020.00031. PMID: 32116655; PMCID: PMC7031158. 4. Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, Babusis D, Tang Y, Shirely MA, Moghaddam MF, Copland JA, Tun HW. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754. doi: 10.1371/journal.pone.0071754. PMID: 23940785; PMCID: PMC3734315.

In vitro protocol:

In vivo protocol:

1. Casu MA, Mocci I, Isola R, Pisanu A, Boi L, Mulas G, Greig NH, Setzu MD, Carta AR. Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson's Disease. Front Aging Neurosci. 2020 Feb 13;12:31. doi: 10.3389/fnagi.2020.00031. PMID: 32116655; PMCID: PMC7031158. 2. Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, Babusis D, Tang Y, Shirely MA, Moghaddam MF, Copland JA, Tun HW. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754. doi: 10.1371/journal.pone.0071754. PMID: 23940785; PMCID: PMC3734315.

1: Malek E, Rana PS, Swamydas M, Daunov M, Miyagi M, Murphy E, Ignatz-Hoover JJ, Metheny L, Kim SJ, Driscoll JJ. The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nat Commun. 2024 Aug 27;15(1):7388. doi: 10.1038/s41467-024-51442-2. PMID: 39191755. 2: Zhou C, Sun C, Huang M, Tang X, Pi L, Li C. Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras. J Med Chem. 2024 Aug 27. doi: 10.1021/acs.jmedchem.4c00815. Epub ahead of print. PMID: 39189384. 3: Richard S, Lesokhin AM, Paul B, Kaufman JL, Pianko M, Biran N, Vij R, Doxie DB, Azeem MI, Martillo M, Wozniak K, Cho HJ, Dhodapkar KM, Dhodapkar MV. Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nat Cancer. 2024 Aug 26. doi: 10.1038/s43018-024-00818-w. Epub ahead of print. PMID: 39187595. 4: Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, Schecter JM, Lendvai N, Patel N, Triguero A, Ursi M. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. J Comp Eff Res. 2024 Sep;13(9):e240080. doi: 10.57264/cer-2024-0080. Epub 2024 Aug 20. PMID: 39162049. 5: Quach H, Parmar G, Ocio EM, Prince HM, Oriol A, Crowther H, Tsukada N, Bories P, Madan S, Nathwani N, Sunami K, Semiond D, Yu D, Cordero P, Macé S, Suzan F, Moreau P. A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2024 Aug 15:0. doi: 10.3324/haematol.2023.284730. Epub ahead of print. PMID: 39157871. 6: Michel CS, Fehr EM, Nolte H, Beck J, Kreft A, Rauschkolb-Olk KT, Jacobi B, Theobald M, Munder M. Effective treatment of refractory monoclonal gammopathy- associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone. EJHaem. 2024 Jun 17;5(4):838-841. doi: 10.1002/jha2.964. PMID: 39157595; PMCID: PMC11327726. 7: Wang Y, Chen K, Zhou S, Zhang W. Multisite distribution of fibrillary inclusions in a patient with light chain proximal tubulopathy: A case report. Medicine (Baltimore). 2024 Aug 16;103(33):e39174. doi: 10.1097/MD.0000000000039174. PMID: 39151531; PMCID: PMC11332701. 8: Xu Q, Feng H, Li Z, Shao X. Acetyl-CoA Carboxylase Proteolysis-Targeting Chimeras: Conceptual Design and Application as Insecticides. J Agric Food Chem. 2024 Aug 28;72(34):18809-18815. doi: 10.1021/acs.jafc.4c02793. Epub 2024 Aug 15. PMID: 39145990. 9: Debbi K, Loganadane G, Roulin L, Belhadj K, Boukhobza C, Saoudi A, Grellier N, Belkacemi Y. Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe! Rep Pract Oncol Radiother. 2024 Jul 22;29(3):409-411. doi: 10.5603/rpor.100780. PMID: 39144268; PMCID: PMC11321792. 10: Meraz-Munoz A, Mian H, Kirkwood D, Jeyakumar N, McCurdy A, Tangri N, Saskin R, Leung N, Wald R, Kitchlu A. Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real- World, Population-Based Cohort Study. Clin Lymphoma Myeloma Leuk. 2024 Jul 15:S2152-2650(24)00265-9. doi: 10.1016/j.clml.2024.07.007. Epub ahead of print. PMID: 39117532. 11: Cholujova D, Bujnakova ZL, Dutkova E, Valuskova Z, Csicsatkova N, Suroviakova K, Marinkovicova ME, Zbellova L, Koklesova L, Sedlak J, Hideshima T, Anderson KC, Jakubikova J. Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies. Nanomedicine. 2024 Aug 5;62:102777. doi: 10.1016/j.nano.2024.102777. Epub ahead of print. PMID: 39111377. 12: Ichiyama K, Long J, Kobayashi Y, Horita Y, Kinoshita T, Nakamura Y, Kominami C, Georgopoulos K, Sakaguchi S. Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity. Immunity. 2024 Jul 30:S1074-7613(24)00359-5. doi: 10.1016/j.immuni.2024.07.010. Epub ahead of print. PMID: 39111316. 13: Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, He J, Kharat A, Cost P, Valluri S, Yong KL. Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Adv. 2024 Aug 7:bloodadvances.2024012640. doi: 10.1182/bloodadvances.2024012640. Epub ahead of print. PMID: 39110988. 14: Delea TE, Ma Q, Kroog GS, Ge W, Moynahan A, Sabater Anaya N, Rodriguez Lorenc K, Song X. From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncol Ther. 2024 Sep;12(3):565-583. doi: 10.1007/s40487-024-00291-6. Epub 2024 Aug 4. PMID: 39097860; PMCID: PMC11333644. 15: Zolotov E, Kabat M, Parmar H, Anand P, Zenreich J, Aleman A, Phull P, Doucette K, Vesole DH, Siegel DS, Biran N. Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study. Leuk Lymphoma. 2024 Jul 31:1-9. doi: 10.1080/10428194.2024.2385501. Epub ahead of print. PMID: 39082756. 16: Voorhees PM, Suman V, Efebera YA, Raje N, Tuchman SA, Rodriguez C, Laubach JP, Bova-Solem M, Carlisle D, Usmani SZ, McCarthy PL, Richardson PG. Alliance A061202: Ixazomib, pomalidomide and dexamethasone for lenalidomide-refractory multiple myeloma in first relapse. Blood Adv. 2024 Jul 26:bloodadvances.2024013623. doi: 10.1182/bloodadvances.2024013623. Epub ahead of print. PMID: 39058954. 17: Osipyan A, Bulai RG, Wu Z, de Witte J, van der Velde JJH, Kader M, van der Wouden PE, Poelarends GJ, Dekker FJ. The synthesis of 1,2,3-triazoles as binders of D-dopachrome tautomerase (D-DT) for the development of dual-targeting inhibitors. Eur J Med Chem. 2024 Oct 5;276:116665. doi: 10.1016/j.ejmech.2024.116665. Epub 2024 Jul 8. PMID: 39013358. 18: Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Jun 24:S2152-2650(24)00238-6. doi: 10.1016/j.clml.2024.06.004. Epub ahead of print. PMID: 39003099. 19: Weng C, Zhou Y, Zhang L, Wang G, Ding Z, Xue L, Liu Z. Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis. Semin Arthritis Rheum. 2024 Jun 27;68:152500. doi: 10.1016/j.semarthrit.2024.152500. Epub ahead of print. PMID: 39002345. 20: Fujii S, Miura Y. Lenalidomide and pomalidomide modulate hematopoietic cell expansion and differentiation in the presence of MSC. Int J Hematol. 2024 Jul 12. doi: 10.1007/s12185-024-03815-y. Epub ahead of print. PMID: 38995485.